Objective: Necrotic cells evoke potent innate immune responses through unclear mechanisms. The mitochondrial fraction of the cell retains constituents of its bacterial ancestors, including N-formyl peptides, which are potentially immunogenic. Thus, we hypothesized that the mitochondrial fraction of the cell, particularly N-formyl peptides, contributes significantly to the activation of monocytes by necrotic cells.
A cute cell or tissue damage is known to promote inflammatory responses; however, the mechanisms have only recently been explored. Previous studies suggested that monocyte activation in response to cell necrosis is consequent to the liberation of a nuclear transcription factor, high mobility group box 1 (HMGB1), through the activation of re-ceptors for advanced glycation end products (1) . Receptors for advanced glycation end products activation, in turn, initiates various proinflammatory events, including the recruitment of inflammatory cells and the production of proinflammatory cytokines (2, 3) . However, new evidence indicates that HMGB1 is not essential for immune responses to necrotic cells in vivo (4) , and other potentially immunogenic cell components, including DNA (5) and lipid membranes (6) , should be considered in the context of inflammatory responses to damaged cells, such as occurs during trauma, pancreatitis, ischemia, severe systemic infections, and other acute illnesses. In this regard, a systematic analysis of the inflammatory properties of necrotic cell components has not been performed.
Acute, life-threatening illness is associated with characteristic changes in cell morphology and function with mitochondrial pathology being among the earliest manifestations (7, 8) . Recent studies in-dicate that mitochondrial proteins are released under conditions associated with cell death (9) or tissue damage (10, 11) , which has interesting implications for triggering immune responses.
Mitochondria are unique in that they are derived from bacterial ancestors and retain many of their features, including a circular genome, unique cell membrane lipids (e.g., cardiolipin), and N-formyl peptides, which are distinct byproducts of mitochondrial DNA (mtDNA) expression in mammalian cells. Like their bacterial homologues, mtDNA-encoded N-formyl proteins serve as potent chemoattractants for neutrophils when released from degenerating mitochondria in the context of necrotic cell death (12, 13) and are recognized by high-affinity formyl peptide receptors (FPR) and formyl peptidelike 1 receptors on various immune cells (14, 15) . Furthermore, mtDNA is rich in cytosine-phosphate-guanosine sites dinucleotides, which are recognized by intracellular Toll-like receptor 9 in spe-cific immune cells, including monocytes (16) . In mammals, the inner mitochondrial membrane is the only source of cardiolipin, which is potentially antigenic but does not directly induce innate immune responses (17) . Finally, the immunostimulatory activity of mitochondrial transcription factor A (TFAM), the structural and functional homolog of HMGB1 (18) , a potent proinflammatory mediator (2, 3) , has not been considered. Based upon these observations, we hypothesized that the mitochondrial component of necrotic cells, particularly N-formyl peptides, mtDNA, and TFAM, would activate human peripheral blood monocytes.
MATERIALS AND METHODS
Reagents and Cell Culture. Bacterial Nformyl-Met-Leu-Phe and purified cardiolipin were obtained from Sigma (St. Louis, MO). Human N-formyl peptide ͓fMMYALF, the N-terminal sequence of mitochondrial nicotinamide adenine dinucleotide dehydrogenase subunit 6 (ND6)͔ was synthesized by Gen-Script (Piscataway, NJ). Cyclosporine H (CsH), Boc-Phe-Leu-Phe-Leu-Phe, and pertussis toxin were acquired from Axxora, LLC (San Diego, CA), ChemPep, (Miami, FL), and Calbiochem (San Diego, CA), respectively. Most primary antibodies directed against specific proteins were obtained commercially: HMGB1 and CEACAM-1 (R&D Systems; Minneapolis, MN); cytochrome c oxidase, subunit II (Mito-Sciences, Eugene, OR); calnexin and heat shock protein 60 (Abcam, Cambridge, MA), and ND1, ND6, ␤-actin, and glyceraldehyde 3-phosphate dehydrogenase (Santa Cruz Biotechnology, Santa Cruz, CA). Anti-TFAM polyclonal antibody was made by Spring Valley Laboratories (Woodbine, MD). The epitope used to create the antibody was KQRKYG, which was chosen because the corresponding peptide sequence was unique relative to that of HMGB1. Secondary antibodies were acquired from Cell Signaling Technology (Danvers, MA). HepG2 and HEK-293 cells were purchased from the American Type Culture Collection (Manassas, VA) and cultured using Dulbecco's modified Eagle's medium (DMEM)/ F-12 and MEM media (Invitrogen, Carlsbad, CA), respectively. Unless otherwise stated, all additional chemicals were obtained from Sigma using the best available grade.
Establishment of HepG2 Rho(0) Cell Lines. HepG2 cells depleted of mtDNA and mtDNAencoded proteins were generated using the protocol described by King and Attardi (19) . In brief, HepG2 cells were cultured in DMEM/ F-12 medium supplemented by equal amounts (100 g/mL) of uridine and pyruvate and treated with 100 ng/mL ethidium bromide for 6 -8 weeks. Suppression of mtDNA-encoded genes and proteins was confirmed by evaluating mtDNA gene expression using real-time polymerase chain reaction (PCR), performing Western blot analysis using anti-cytochrome c oxidase, subunit II antibody, and examining cytochrome c oxidase activity using the Cytochrome c Oxidase Assay kit (Sigma) according to the manufacturer's instructions.
Subcellular Fractionation. HepG2 cell necrosis was induced by freeze/thaw, as described by Scaffidi et al (1) , or by heating (44°C for 60 minutes) and was confirmed by the lactate dehydrogenase assay (94.7 Ϯ 4.9% vs. 86.2 Ϯ 5.4% cell death). Nuclear, cytoplasmic, and total mitochondrial protein fractions, along with submitochondrial particles, were prepared from HepG2 cells using a differential centrifugation approach as described by Nair and McGuire (20) with minor modifications. Briefly, HepG2 cells were suspended in mitochondrial isolation buffer (230 mM mannitol, 70 mM sucrose, 3 mM HEPES ͓pH 7.4͔, 1 mM EGTA, 1 mM EDTA, 0.5 mg/mL fatty acid-free bovine serum albumin, 1 mM phenylmethylsulfonylfluoride, 10 L/mL protease inhibitor cocktail) in the presence or absence of 50 U/mL benzonase (Novagen; San Diego, CA), as indicated. Following freeze/thaw or heating, the necrotic HepG2 cell suspension was centrifuged at 300g for 10 minutes at 4°C to pellet unlysed cells and the nuclear fraction. The resultant supernatant was centrifuged again at 1500g for 10 minutes at 4°C to assure removal of nuclear contaminants. The supernatant was then centrifuged at 7000g for 15 minutes at 4°C to separate mitochondrial (pellet) from cytoplasmic (supernatant) fractions. The cytoplasmic fraction was centrifuged again at 10,000g for 15 minutes at 4°C to exclude any mitochondria. The mitochondrial pellet was resuspended and lysed by three 5-minute freeze/thaw cycles using a dry ice/ethanol bath and a 37°C water bath to obtain soluble total mitochondrial proteins. These proteins were then centrifuged at 144,000g for 1 hour at 4°C to separate soluble intermembrane and matrix proteins from the mitochondrial inner and outer membranes. The mitochondrial membrane pellet was resuspended and incubated in 2% 3-([3-cholamidopropyl]dimethylammonio)-1-propanesulfonic acid in Tris-buffered saline (25 mM Tris ͓pH 7.2͔), 0.15 M NaCl). The final supernatant, containing soluble mitochondrial membrane proteins, was then exchanged to PBS buffer using a desalting column (Amersham Biosciences; Piscataway, NJ). Purity of the mitochondrial protein fractions was confirmed by Western blot using antibodies against markers specific for plasma membrane (CEACAM-1), endoplasmic reticulum (calnexin), and mitochondria (cytochrome c oxidase, subunit II, heat shock protein 60) ( Fig. 1 ). Glyceraldehyde 3-phosphate dehydrogenase served as a loading control.
Cytotoxicity of HepG2 Preparations. HepG2 cell death following freeze/thaw or heating was examined by analyzing the lactate dehydrogenase concentration in the collected supernatant samples (Cytotoxicity Detection kit; Roche Applied Science, Indianapolis, IN).
Lactate dehydrogenase content was measured spectrophotometrically at 490 nm according to the manufacturer's instructions and normalized to matching samples wherein cells were incubated for 60 minutes with 2% Triton X-100.
Plasmid Construction and Purification of Recombinant HMGB1 and TFAM. The coding region of human TFAM (GenBank Accession No. BC126366) and HMGB1 (GenBank Accession No. BC003378) were amplified by PCR using pT7-7-TFAM and pCMV-Sports6-HMGB1 (provided by Gerald Shadel, PhD) as templates. The sense primers for TFAM (5Ј-CCGAATTCCCACCATGTCATCTGTCTTG-GCAAGT-3Ј) and HMGB1 (5Ј-CCGAATTC-CCACCATGGGCAAAGGAGATCCTAAG-3Ј) introduced a consensus Kozak translation initiation sequence and an EcoRI restriction site to facilitate cloning. The antisense primers of TFAM (5Ј-CCAAGCTTACACTCCTCAG-CACCATATT-3Ј) and HMGB1 (5Ј-CCAA-GCTTTTCATCATCATCATCTTCTTCT-3Ј) introduced a HindIII restriction site. The PCR product was digested with EcoRI and HindIII, cloned into a pcDNA3.1(-)/myc-His A vector (Invitrogen) in-frame with a C-terminal myc epitope and 6ϫ histidine tags and then transformed into Escherichia coli-competent cells (DH5␣, Invitrogen). The sequences of TFAM and HMGB1 with the myc/His tag were confirmed by DNA sequencing. The pcDNA3.1-TFAM.myc.6ϫ His and pcDNA3.1-HMGB1.myc.6ϫ His plasmids were transfected into human embroyonic kidney-293 cells using calcium phosphate-DNA coprecipitation. The polyhistidine-tagged recombinant proteins were purified by Ni-NTA nickelchelating resin (Invitrogen) according to the manufacturer's instructions.
The identity and function of the proteins were confirmed by Western blot using specific antibodies against TFAM and HMGB1, capillary-liquid chromatography-nanospray tandem mass spectrometry and the electrophoretic mobility shift assay (see later) ( Fig.  2 ). Proteins evaluated by mass spectrometry were scored based on the number of matching peptide sequences (i.e., hits) and the probability that the match was a random event. This yielded a Mowse score which when Ͼ51 indicated significant identity and/or extensive homology (p Ͻ 0.05). Mass spectrometric analysis confirmed the identities of TFAM and HMGB1 with overall protein coverage corresponding to Mowse scores of 1005 (54% sequence coverage, 258 peptide matches) and 1031 (53% sequence coverage, 293 peptide matches), respectively.
Electrophoretic Mobility Shift Assay for TFAM and HMGB1. Synthetic cruciform DNA (four-way DNA junctions) for the HMGB1 gel shift assay was constructed according to published protocols (21, 22) . Cruciform DNA was prepared by annealing the following four oligonucleotides synthesized (from 5Ј to 3Ј) with two of them 32 P-end-labeled: strand 1) CCCTATAACCCCTGCATTGAATTCCAGTCTGA-TAA; strand 2) GTAGTCGTGATAGGTGCAG-GGGTTATAGGG; strand 3) AACAGTAGCTCTTAT-TCGAGCTCGCGCCCTATCACGACTA, and strand 4) TTTATCAGACTGGAATTCAAGCGCGAG-CTCGAATAAGAGCTACTGT. Similarly, the light strand promoter of mtDNA DNA duplex of 101 bp containing the TFAM-binding site was prepared by annealing oligonucleotides 1 (5Ј-TTAGTAGTATGGGAGTGGGAGGG-GAAAATAATGTGTTAGTTGGGGGGTGACTG-TTAAAAGTGCATACCGCCTAAAAGATAA-AATTTGAAATCTGGTTAGGC-3Ј) and 2 (5Ј-GCCTAACCAGATTTCAAATTTTATCTTTTA-GGCGGTATGCACTTTTAACAGTCACCCCC-CAACAACACATTATTTTCCCCTCCCACTCC-CATACTACTAA-3Ј). All oligonucleotides were highly purified by denaturing polyacrylamide gel electrophoresis and subsequently labeled at their 5Ј-termini by ͓ ␥Ϫ32 P͔ adenosine triphosphate.
Endotoxin Analysis. The endotoxin level in each subcellular fraction protein, formyl-Met-Leu-Phe, fMMYALF and recombinant TFAM and HMGB1 proteins was determined using the chromogenic Limulus amebocyte lysate assay (Associates of Cape Cod; East Falmouth, MA). When needed, samples were passed through AffinityPak Detoxi-Gel columns (Pierce Biotechnology; Rockford, IL) according to the manufacturer's recommendations and retested by Limulus amebocyte lysate to confirm that endotoxin levels were Ͻ5 pg/g protein before later use for monocyte incubations.
Isolation, Culture, and Stimulation of Human Monocytes. Normal peripheral blood monocytes were isolated from healthy human blood donors (n ϭ 10) according to approved university Institutional Review Board guidelines (including signed written informed consent) using the MACS CD14 MicroBead posi-tive selection kit (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions. Monocytes were cultured in 24-well plates at a concentration of 1 ϫ 10 6 /mL in X-VIVO 15 serum-free medium (Lonza Walkersville; Walkersville, MD) at 37°C in a 5% CO 2humidified atmosphere. Polymyxin B (10 g/ mL) was routinely added to the cells in each well (except the lipopolysaccharide-treated positive control well) to further block any possible endotoxin contamination. Desired concentrations of subcellular or mitochondrial fraction proteins were then added to the medium. All preincubations with FPR inhibitors (CsH, 3 M; Boc-Phe-Leu-Phe-Leu-Phe, 10 M) or the small G-protein inhibitor (pertussis toxin, 1 g/mL) were made 30 minutes before protein fraction addition. Monocytes Figure 1 . Verification of subcellular fraction purity. A, Representative Western blot of subcellular fractions (30 g) showed a lack of cytosolic contamination by mitochondrial proteins (heat shock protein 60 ͓HSP60͔, cytochrome c oxidase, subunit II ͓COXII͔) and an absence of ␤-actin in the mitochondrial fractions. Furthermore, the mitochondrial matrix fraction was free from mitochondrial membrane contamination, as reflected by the absence of COXII. The COXII control was derived from human heart mitochondria (MitoSciences, Eugene, OR). Protein loading was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). B, Representative Western blot examining CEACAM-1 and calnexin immunoreactivity confirmed that the mitochondrial and cytosolic fractions (30 g) were not contaminated by plasma membrane or endoplasmic reticulum, respectively. Mito, mitochondrial. transfected to silence FPR1 RNA (see later) were incubated for 24 hours before additions. Further monocyte incubations involved adding N-formyl peptides (formyl-Met-Leu-Phe or fMMYALF at 100 ng/mL) with/without TFAM or HMGB1 (5 g/mL). The cell supernatants were then collected at 3 and 6 hours posttreatment and stored at Ϫ80°C for later analyses. Cell pellets were also obtained and stored in a similar manner for later RNA isolation and analysis. Cytokine Assays. Cell culture supernatants were analyzed for their interleukin (IL)-8 (R&D Systems), IL-6 and tumor necrosis factor-␣ (eBioscience, San Diego, CA) concentrations by enzyme-linked immunosorbent assay according to the manufacturer's recommendations.
FPR Small Interfering RNA and Transfection. Predesigned human FPR1 small interfering RNA (siRNA) was synthesized by Qiagen (Valencia, CA) based on GenBank Accession No. NM002029. The sequences were as follows: sense, r(GCAAGGCAUGUACAAAGAA) dTdT, and antisense, r(UUCUUUGUACAUGC-CUU GC)dAdA. Negative nonsilencing control siRNA (Qiagen), labeled with Alexa Fluor 488 and having no known homology to mammalian genes, was used to control for nonspecific effects. FPR1 siRNA was transfected into monocytes using the Human Monocyte Nucleofector kit (Amaxa, Gaithersburg, MD). In brief, 5 ϫ 10 6 monocytes, resuspended with 100 L human monocyte nucleofector solution, were mixed with 3 g FPR1 siRNA, transferred into an Amaxacertified cuvette and transfected using Nucleofector Program Y-01. FPR gene expression was later evaluated in cell pellets by reverse transcriptase-polymerase chain reaction and real-time PCR. Transfection efficiency was determined in monocytes 24hour posttransfection by analyzing Alexa 488 fluorescence. ␤-actin and CAP1 served as housekeeping gene controls.
Reverse Transcriptase-Polymerase Chain Reaction and Real-Time PCR. Total RNA was isolated from HepG2 and Rho(0)-HepG2 cells as well as normal and FPR1 siRNA-transfected monocytes using the RNeasy Mini kit (Qiagen) according to the manufacturer's recommendations. The quality and concentration of RNA were analyzed using a ND-8000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) and a 2100 BioAnalyzer (Aligent Technologies, Santa Clara, CA). The first strand complementary (cDNA) was synthesized using 1.0 g total RNA by MultiScribe reverse transcriptase (Applied Biosystems, Foster City, CA) with random hexamers in a 50 L reaction volume. Semiquantitative reverse transcriptase-polymerase chain reaction was performed in 50 L containing 1 L of diluted cDNA (1:10) from 50 L cDNAs, 1.5 mM MgCl 2 , 0.2 mM dNTP, 0.5 M of each primer and 1 U of Taq DNA polymerase (Invitrogen). The PCR conditions for FPR1, ␤-actin, and CAP1 were 95°C for 2 minutes, followed by 25 cycles of 95°C for 30 seconds, 56°C for 30 seconds, 72°C for 30 seconds and 72°C for 5 minutes 10 L of PCR product were separated by 1.5% agarose gel electrophoresis and stained with 0.05% ethidium bromide. The primers used in PCR are identified in Table 1 (Integrated DNA Technologies, Coralville, IA).
Real-time PCR was performed in 20 L of a mixture containing 1 L of a cDNA sample, 5 pmol of each primer needed (Table 1) , and ATP synthase 6  72  Sense  5Ј-CCAATAGCCCTGGCCGTAC-3Ј  Antisense  5Ј-CGCTTCCAATTAGGTGCATGA-3Ј  ATP Synthase 8  95  Sense  5Ј-CAACTAAAAATATTAAACACAA-3Ј  Antisense  5Ј-CGTTCATTTTGGTTCTCAGGG-3Ј  ␤-actin  268  Sense  5Ј-GCCAACCGCGAGAAGATGA-3Ј  Antisense  5Ј-TGGTGGTGAAGCTGTAGCC-3Ј  CAP1  80  Sense  5Ј-ATTCCCTGGATTGTGAAATAGTC-3Ј  Antisense  5Ј-ATTAAAGTCACCGCCTTCTGTAG-3Ј  COX I  66  Sense  5Ј-TCCGCTACCATAATCATCGCT-3Ј  Antisense  5Ј-CCGTGGAGTGTGGCGAGT-3Ј  COX II  63  Sense  5Ј-TGCCCGCCATCATCCTA-3Ј  Antisense  5Ј-TCGTCTGTTATGTAAAGGATGCGT-3Ј  COX III  67 Sense
ATP, adenosine triphosphate; COX, cytochrome c oxidase; FPR, formyl peptide receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NADH, nicotinoamide adenine dinucleotide.
10 L of SYBR GREEN PCR master mix (Applied Biosystems). Amplification and detection were achieved with the 7900HT Fast Real-Time PCR System (Applied Biosystems) using the protocol of 50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. The expression of each gene was calculated based on the cycle threshold number and normalized by ␤-actin/CAP1 expression.
Western Blotting. The presence of specific proteins in various subcellular and mitochondrial fractions was determined by Western blot analysis using standard techniques. Protein loading was normalized to glyceraldehyde 3-phosphate dehydrogenase.
Measurement of Lipid and DNA Content in Mitochondrial Preparations. mtDNA content was determined with the fluorescence-based Quant-iT PicoGreen dsDNA Kit (Molecular Probes, Eugene, OR), which has a sensitivity as low as 25 pg/mL DNA. Mitochondrial lipid content was determined by gas-liquid chromatography after samples had been prepared according to Folch et al (23) . DNA and lipid contents were normalized to protein concentration.
Statistical Analyses. The data were derived from at least five independent experiments and were expressed as mean Ϯ SEM, and statistical significance was based on a value of p Յ 0.05. SigmaPlot 10.0 and SYSTAT 12.0 software were used to plot the data and carry out the statistical analyses, respectively. Comparisons of IL-8 release following the treatment of mitochondrial protein under Rho(0) conditions and FPR expression after RNA silencing were carried out using the Wilcoxon rank sum test. Additional comparisons of IL-8 release following the treatment of mitochondrial protein or cell lysates with or without pharmacologic inhibitors or RNA silencing, necrotic cell supernatants, or N-formyl peptides Ϯ TFAM/HMGB1 were made using the Kruskal-Wallis test. Where appropriate, post hoc analyses between groups were performed using Dunn's test if the Kruskal-Wallis overall p value was significant.
RESULTS
Necrotic Cells Passively Release Mitochondrial Proteins. HepG2 cells exposed to freeze/thaw, heating, or detergent were shown to release mitochondrial proteins into the surrounding medium in the absence of cell manipulation (e.g., vortex or cell agitation) (Fig. 3A) . The mixture of mitochondrial and nonmitochondrial (e.g., HMGB1) proteins released from ne-crotic cells was shown to activate human monocytes (Fig. 3B) .
Monocytes Are Primarily Activated by the Mitochondrial Component of Necrotic Liver Cells. Necrotic HepG2 cells were fractionated into nuclear, cytoplasmic, mitochondrial, and submitochondrial fractions and compared in terms of promoting monocyte activation, as reflected by IL-8 release. As shown in Figure 4A , the mitochondrial fraction of HepG2 cells, particularly the mitochondrial membrane, was the most potent inducer of IL-8 release by human peripheral blood monocytes. Nearly identical results were obtained when immune responses to monocyte treatment with matching heat-killed HepG2 cell components were determined (data not shown). Thus, all subsequent experiments were conducted using freeze/thaw cell preparations. Figure 4B shows similar dosedependent induction of monocyte IL-8 release from mitochondrial preparations derived from either human liver or from HepG2 cells.
The observed proinflammatory effect of mitochondria was apparently mediated by one or more mitochondrial proteins, because depletion of mitochondrial CpGcontaining DNA and mitochondrial lipids had no significant effect on this response (Fig. 5 ). Furthermore, treatment of monocytes with purified cardiolipin (5 g/mL) did not induce monocyte IL-8 release (917.0 Ϯ 153.3 vs. 879.5 Ϯ 53.2 pg/mL). With respect to the nature of the cytokine response, monocyte IL-8 release occurred at much lower concentrations of mitochondrial protein than were required to promote IL-6 or tumor necrosis factor-␣ release (Fig. 6 ). Thus, one or more of the proteins localized to mitochondrial membranes were recognized by monocyte receptors to trigger the release of IL-8.
Depletion of Mitochondrial N-Formyl Peptides Attenuates Monocyte IL-8 Responses to Mitochondrial Proteins.
HepG2 Rho(0) cells, which are selectively depleted of mtDNA (Table 2 ) and consequently N-formyl peptides (Fig. 7A) , exhibited the expected reduction in mitochondrial respiratory activity (Fig. 7B) . Compared with mitochondrial proteins derived from untreated HepG2 cells, monocyte IL-8 responses to mitochondrial fractions from Rho(0) cells were significantly attenuated (Fig. 7C) . Thus, N-formyl peptides appear to be integral to the activation of human monocytes by mitochondrial proteins.
Suppression of High-Affinity FPR Activity Attenuates IL-8 Release by Monocytes in Response to Mitochondrial
Proteins. To the extent that mitochondrial N-formyl peptides are responsible for the activation of monocytes, we reasoned that the observed IL-8 response was dependent upon interaction with FPR. CsH significantly attenuated the monocyte response to treatment with necrotic HepG2 cell lysates (Fig. 8A) , and both CsH and Boc-Phe-Leu-Phe-Leu-Phe strongly suppressed IL-8 release from monocytes exposed to mitochondrial proteins; whereas, reduction by pertussis toxin was not significant (Fig. 8B ). In keeping with these results, suppression of FPR expression by siRNA (Fig. 9A ) dramatically inhibited monocyte IL-8 release in response to mitochondrial proteins (Fig. 9B ).
Bacterial and Mitochondrial N-Formyl Peptides Do not Directly Activate Monocytes. To determine whether N-formyl peptides are sufficient to induce monocyte IL-8 release, synthetic bacterial N-formyl-Met-Leu-Phe or the immunogenic N-formyl peptide sequence (fMMYALF) of mitochondrial nicotinamide adenine dinucleotide dehydrogenase subunit 6 (14) were administered to human monocytes. Unexpectedly, these highly purified N-formyl peptides did not induce significant monocyte IL-8 release when administered alone (Fig. 10B) . Given that N-formyl peptides and FPR interactions are essential for monocyte IL-8 release in response to mitochondrial membrane proteins, as shown above, we reasoned that the FPR-induced response required a second proinflammatory stimulus, presumably in response to other immunogenic mitochondrial components. Thus, we determined whether mtDNA, which contains CpG DNA motifs, or mitochondrial TFAM, which is homologous in structure and function to HMGB1 (18) and is localized to inner mitochondrial membranes in association with complex I of the electron transport chain (24) (i.e., containing Nformyl peptides), act synergistically with N-formyl peptides to induce monocyte activation. After confirming that TFAM was concentrated in the mitochondrial membrane fraction of the cell (Fig. 10A) , we investigated whether TFAM or combinations of TFAM ϩ N-formyl peptides would induce monocyte activation. Neither highly purified (endotoxin-free) recombinant human TFAM nor HMGB1, when administered alone, activated monocytes, except at concentrations exceeding 1.0 g/mL. However, ng/mL concentrations of synthetic Nformyl peptides promoted monocyte activation in the presence of either HMGB1 or TFAM. The combination of N-formyl peptides and cytosine-phosphate-guanosine sites DNA exhibited no significant synergy (data not shown) consistent with the earlier finding that depletion of DNA from mitochondrial protein samples had little effect on their induction of monocyte IL-8 release (Fig. 5 ). In addition, monocyte activation in response to the combination of TFAM ϩ N-formyl peptides was inhibited by CsH ( Fig. 10B) ; whereas, IL-8 release was not influenced by the FPR1 inhibitor, WRW4 (data not shown).
DISCUSSION
The innate immune response triggered by damaged tissues in the context of acute illness, such as pancreatitis, burns, or trauma, has important implications for the survival of the host. The systemic release of proinflammatory cytokines under these conditions promotes the recruitment and activation of various immune cells, which on the one hand facilitates the removal of necrotic debris and sanitizes the damaged tissue, whereas on the other hand contributing to further inflammation, resulting in progressive cell and tissue damage. The persistence of systemic inflammation and progression of organ dysfunction that commonly occurs in the setting of severe acute illnesses is highly predictive of an adverse outcome in critically ill patients (25, 26) . However, other than supportive care, there are no effective treatments to interrupt this cycle of tissue damage and inflammation, and the mechanisms driving this sort of inflammation are not completely understood. This study provides evidence that the mitochondrial component of the cell, particularly mitochondrial membrane proteins (N-formyl peptides, TFAM), contributes significantly to the induction of the innate immune response to necrotic cells.
Recent studies have considered the mechanisms by which the innate immune response is regulated by damaged cells. As with autoimmune diseases wherein "sequestered antigens" released from dying cells at the site of inflammation trigger adaptive immune responses (27) , self-antigens released from necrotic cells during acute illness are shown to promote innate immune responses (28) . The same is not true for apoptotic cells, wherein potentially proinflammatory antigens, including proteins, DNA, and RNA, are effectively packaged and enzymatically degraded (29) . Furthermore, specific cell surface antigens expressed on apoptotic cell membranes actually suppress the responsiveness of phagocytes that are engaged in their clearance (30) . Thus, apoptotic cell death is advantageous from the standpoint of minimizing inflammatory responses in the context of removing damaged or senescent cells. Identification of the specific antigens released from necrotic cells and their corresponding immune cell receptors provides novel insight into the pathogenesis of local and systemic inflammation under conditions favoring cell necrosis. Investigations by Scaffidi et al (1) suggested that the nuclear chromatin-binding protein, HMGB1, is primarily responsible for the activation of monocytes in the context of cell necrosis. However, more recent studies indicate that highly purified (endotoxin-free) HMGB1 lacks proinflammatory actions, unless combined with other antigens, such as CpG dinucleotides (31) or bacterial lipopolysaccharides (32) . Furthermore, necrotic cells deficient in HMGB1 are shown to strongly induce inflammation in vivo (4) . Thus, other intracellular antigens are incriminated.
The immune system of humans retains highly conserved "pattern-recognizing" receptors, including Toll-like receptors, nucleotide binding oligomerization domains, and FPRs, which are extremely sensitive to the presence of potential environmental pathogens, including bacte-ria, fungi, and viruses. Like bacteria, eukaryotic mitochondria possess circular DNA, which contains CpG DNA motifs and encodes specific high-abundance Nformyl peptides. All 13 proteins encoded by mtDNA possess N-formyl peptide sequences, and these proteins are found exclusively in the mitochondrial inner membrane, where they participate in electron transport (33) . As with their bacterial homologues, mitochondrial N-formyl peptides are potent chemotaxins for neutrophils (12) and are recognized by the high-affinity FPR (14) . TFAM, a critical regulator of mtDNA transcription, is associated with the inner mitochondrial membrane and with mtDNA (24) . TFAM is a structural and functional homolog of HMGB1; however, the amino acid sequence differs significantly (18) . To the extent that TFAM and HMGB1 share a common proinflammatory active site, it follows that TFAM released from damaged cells may be recognized by the immune system through various Toll-like receptors (34) and/or receptors for advanced glycation end prod-ucts (31) , which would contribute to local (35) and systemic inflammation (36) . Thus, the release of mitochondrial antigens in the context of cell and tissue damage (10, 37) could have important implications for the perpetuation of inflammation during acute illness.
Our data indicate that monocytes respond vigorously to mitochondrial proteins, and N-formyl peptides contribute significantly to this response. FPRs are critical for antibacterial responses, promoting neutrophil chemotaxis to either bacterial or mitochondrial N-formyl peptides (12) . IL-8, a potent inducer of neutrophil chemotaxis, was the primary cytokine produced by monocytes on exposure to low concentrations of mitochondrial proteins or necrotic cells. This finding is in keeping with the observed neutrophil recruitment in the acute phase of tissue damage (38) , which serves the dual purpose of decontaminating the wound while removing necrotic debris. The immune response to necrotic cells resembles that mounted against potential invading organisms, wherein interactions between bacterial N-formyl peptides and host FPR promote the chemoattraction of phagocytes to the site of infection (39) . Like monocytes, neutrophils exposed to bacterial N-formyl peptides exhibit no significant IL-8 production unless they are costimulated by another antigen, such as fibrinogen (40) . The role of TFAM and HMGB1 in the activation of monocytes and other cells participating in the innate immune response to necrotic cells is unclear. We show that TFAM is localized to the inner mitochondrial membrane and that monocytes respond most vigorously to the mitochondrial membrane fraction of the cell. Furthermore, TFAM, like HMGB1, is released from necrotic cells and synergizes with N-formyl peptides to promote monocyte activation. However, it is unclear whether TFAM is essential for the activation of monocytes in the context of cell necrosis, and the monocyte receptor(s) that respond to TFAM remain to be determined. However, it is clear from these investigations that TFAM and/or HMGB1 are capable of interacting with bacterial or mitochondrial N-formyl peptides to promote monocyte IL-8 release, all of which are present in lysates of necrotic cells. A specific role of FPR in monocyte cytokine responses to mitochondrial proteins is a new finding and is suggested by several lines of evidence. FPR is known to engage mitochondrial and bacterial N-formyl Figure 10 . N-formyl peptides alone are insufficient to induce monocyte interleukin (IL)-8 release. A, Representative Western blot analysis showed mitochondrial transcription factor A (TFAM) to be concentrated in the mitochondrial membrane fraction of the cell (protein load: 30 g). B, Monocyte IL-8 responses to mitochondrial (fMMYALF) or bacterial (formyl-Met-Leu-Phe ͓fMLP͔) N-formyl peptides (100 ng/mL) in the presence or absence of mitochondrial (TFAM) or nuclear (high mobility group box 1 ͓HMGB1͔) chromatin-binding proteins (5 g/mL) and cyclosporine H (CsH; 3 M) treatment (*p Ͻ 0.05, relative to control; †p Ͻ 0.05, compared with matching treatment with TFAM or HMGB1 alone; ‡p Ͻ 0.05, relative to matching treatment in the absence of CsH). Lipopolysaccharide (LPS) (10 ng/mL) was used as a positive control.
